27 Scopus citations


Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in western populations, and is closely associated with features of the metabolic syndrome. The burden of disease is set to rise exponentially, and this is further compounded by the lack of good medications. In addition, these patients tend to have multiple comorbidities that may not be adequately managed. In this article, we review the biological basis of potential therapies in nonalcoholic steatohepatitis (NASH), the current drugs being tested in clinical trials, as well some practical considerations in managing patients in the clinic.

Original languageEnglish (US)
Article numbere00105
JournalEndocrinology, Diabetes and Metabolism
Issue number4
StatePublished - Oct 1 2020


  • drug development
  • drug therapy
  • nonalcoholic steatohepatitis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Drug discovery and treatment paradigms in nonalcoholic steatohepatitis'. Together they form a unique fingerprint.

Cite this